Document Detail


The translational imperative: making cell therapy simple and effective.
MedLine Citation:
PMID:  22776825     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The current practice of cell therapy, in which multipotent or terminally differentiated cells are injected into tissues or intravenously, is inefficient. Few therapeutic cells are retained at the site of administration and engraftment is low. An injectable and biologically appropriate vehicle for delivery, retention, growth and differentiation of therapeutic cells is needed to improve the efficacy of cell therapy. We focus on a hyaluronan-based semi-synthetic extracellular matrix (sECM), HyStem®, which is a manufacturable, approvable and affordable clinical product. The composition of this sECM can be customized for use with mesenchymal stem cells as well as cells derived from embryonic or induced pluripotent sources. In addition, it can support therapeutic uses of progenitor and mature cell populations obtained from skin, fat, liver, heart, muscle, bone, cartilage, nerves and other tissues. This overview presents four pre-clinical uses of HyStem® for cell therapy to repair injured vocal folds, improve post-myocardial infarct heart function, regenerate damaged liver tissue and restore brain function following ischemic stroke. Finally, we address the real-world limitations - manufacture, regulation, market acceptance and financing - surrounding cell therapy and the development of clinical combination products.
Authors:
Glenn D Prestwich; Isaac E Erickson; Thomas I Zarembinski; Michael West; William P Tew
Related Documents :
22563055 - Cardiac-specific deletion of the microtubule-binding protein cenp-f causes dilated card...
16476735 - Systematic evaluation of transcellular activities of secretory phospholipases a2. high ...
18794815 - Stem cells for kidney repair: useful tool for acute renal failure?
17879965 - Calcium oxalate crystals in fetal bovine serum: implications for cell culture, phagocyt...
13938025 - On the structural continuities of the transverse tubular system of rabbit and human myo...
21674435 - Cytotoxicity of ethanolic extracts of artemisia annua to molt-4 human leukemia cells.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review     Date:  2012-07-07
Journal Detail:
Title:  Acta biomaterialia     Volume:  8     ISSN:  1878-7568     ISO Abbreviation:  Acta Biomater     Publication Date:  2012 Dec 
Date Detail:
Created Date:  2012-11-02     Completed Date:  2013-04-03     Revised Date:  2013-12-05    
Medline Journal Info:
Nlm Unique ID:  101233144     Medline TA:  Acta Biomater     Country:  England    
Other Details:
Languages:  eng     Pagination:  4200-7     Citation Subset:  IM    
Copyright Information:
Copyright © 2012 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Brain Ischemia / therapy
Cell- and Tissue-Based Therapy / methods*
Embryonic Stem Cells / cytology,  transplantation
Extracellular Matrix / transplantation*
Humans
Hyaluronic Acid / therapeutic use*
Induced Pluripotent Stem Cells / cytology,  transplantation
Liver Regeneration
Mesenchymal Stem Cell Transplantation
Mesenchymal Stromal Cells / cytology
Myocardial Infarction / therapy
Stroke / therapy
Vocal Cords
Grant Support
ID/Acronym/Agency:
R01 DC 04336/DC/NIDCD NIH HHS; R01 DC004336/DC/NIDCD NIH HHS; R01 DC009600/DC/NIDCD NIH HHS
Chemical
Reg. No./Substance:
9004-61-9/Hyaluronic Acid
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Dapagliflozin monotherapy in drug-naïve patients with diabetes: a randomised controlled trial of lo...
Next Document:  Reduced folate, increased vitamin B(12) and homocysteine concentrations in women delivering preterm.